Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
Status:
Completed
Trial end date:
2017-11-14
Target enrollment:
Participant gender:
Summary
HIV-infected people have an increased risk of developing active tuberculosis (TB). At the
time the study was designed, the standard course of treatment for TB was 6 to 9 months of
isoniazid (INH).This study compared the safety and effectiveness of a 4-week regimen of
rifapentine (RPT) plus INH versus a standard 9-month regimen of INH in HIV-infected people
who are at risk of developing active TB.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Isoniazid Pyridoxal Pyridoxine Rifampin Rifapentine Vitamin B 6 Vitamin B Complex Vitamins